TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903
Amyloidosis, Cardiomyopathies
La Jolla, California, United States
View Trial DetailsNCT Number: NCT07358078
The purpose of this study is to:
* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Interested in participating?
Request Info18 year and older
All sexes
Observational
Clinical Trial Site, Naples, Florida, United States
Each site will invite all eligible patients to participate. Patients will be followed for up to 5 years or until patient withdrawal of consent, loss to follow-up, death, or the end of the study, whichever comes first.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From time of ATTR-CM diagnosis up to 5 years
The NYHA functional classification categorizes the severity of heart failure. Patients are classified in 1 of 4 categories based on their physical limitations, as follows:
Time frame: From time of enrollment for up to 5 years
The clinician-reported outcome of ODI, which measures any post-diagnosis initiation or increase in the dose of loop diuretics, may help identify patients with ATTR-CM who are at an increased risk for adverse outcomes. ODI, a marker to monitor disease progression and/or worsening heart failure, is associated with a higher risk of all-cause mortality, cardiovascular hospitalizations, and urgent heart failure visits. Clinicians monitor ODI to help manage patients with ATTR-CM.
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Norfolk-QoL-DN: The Norfolk QOL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that assesses 6 domains: physical function, large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. The total score ranges from -4 points (best possible quality of life) to 136 points (worst possible quality of life).
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
The KCCQ is a 23-item self-administered questionnaire developed to independently measure the patient's perception of health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life within a 2-week recall period. The KCCQ quantifies 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary [OS] scores).
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
The PGI-C is a 7-point numerical rating scale where 1 indicates "very much improved" and 7 indicates "very much worse."
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
The PGI-S is a 7-point numerical rating scale where 1 indicates "very much improved" and 7 indicates "very much worse."
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
TSQM-9 is a 9-item general instrument that measures the major dimensions of satisfaction with a medication. The questionnaire consists of 3 domains: effectiveness, convenience and side effects. The scores of each domain range from 0 to 100 with higher scores representing higher satisfaction on that domain.
Contact information is provided by the study sponsor or research team.
Clinical Trial Information Line
CONTACT
1-877-ALNYLAM
Clinical Trial Information Line
CONTACT
Alnylam Pharmaceuticals
Industry
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting
Acronym: DemonsTTRate
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07052903
Amyloidosis, Cardiomyopathies
La Jolla, California, United States
View Trial DetailsNCT07654855
Amyloidosis, Hereditary, Transthyretin-Related, Transthyretin Amyloidosis
View Trial DetailsNCT06563895
Alzheimer Disease, Amyloid Cardiomyopathy
La Jolla, California, United States
View Trial DetailsNCT06128629
Amyloidosis, Amyloidosis, Familial
Tucson, Arizona, United States
View Trial Details